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The field of primary immunodeficiencies has pioneered many of the advances in
haematopoietic stem cell transplantation and cellular therapies over the last 50 years.
The first patients to demonstrate sustained benefit and prolonged cure from the
primary genetic defect following allogeneic haematopoietic stem cell transplantation
were patients with primary immunodeficiencies. Although primary immunodeficiency
patients began the modern era of haematopoietic stem cell transplantation, the history
is nevertheless short-in answer to the question “what is the long term outcome of
patients transplanted for primary immunodeficiencies?” we often have to say that we
do not know. We believe that most patients who undergo haematopoietic stem cell
transplantation for primary immunodeficiencies should live a normal lifespan with a fully
corrected immune system. We are now beginning to understanding long term outcomes,
the relationship to the underlying genetic defect, age, and pre-morbid condition of
the patient at time of transplantation, stem cell source and donor, and effect of
pre-transplant cytoreductive chemotherapy conditioning. The long term consequences
of post-transplant complications such as graft vs. host disease, veno-occlusive disease,
or immune dysregulation are also being recognized. Additionally, some genetic defects
have a systemic distribution, and we are learning the natural history of these defects once
the immunodeficiency has been removed.
Keywords: primary immunodeficiency, severe combined immnunodeficiency, Wiskott Aldrich syndrome, chronic
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The field of primary immunodeficiencies has pioneered the way in many of the advances
in hematopoietic stem cell transplantation and cellular therapies over the last 50 years.
In 1968, three patients with primary immunodeficiencies—one with Wiskott Aldrich
syndrome and two with X-linked severe combined immunodeficiencies—were the first
patients to demonstrate sustained benefit and prolonged cure from the primary genetic
defect following allogeneic hematopoietic stem cell transplantation (1–3). The story of
our specialty, whilst at the inception of hematopoietic stem cell transplantation, is thus
short—in answer to the question “what is the long term outcome of patients transplanted
for primary immunodeficiencies?,” we often have to say that we do not really know.
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We believe, in many cases, that patients who undergo
hematopoietic stem cell transplantation for primary
immunodeficiencies will live a normal lifespan with a fully
corrected immune system. However, it is only now that
we are beginning to dissect long term outcomes and the
relationship to the underlying genetic defect, age and pre-morbid
condition of the patient at time of transplantation, stem cell
source and donor, and effect of pre-transplant cytoreductive
chemotherapy conditioning (4–8). The long term consequences
of post-transplant complications such as graft vs. host disease,
veno-occlusive disease or immune dysregulation are also being
recognized. Additionally, some genetic defects have a systemic
distribution, and we are learning the natural history of these
defects once the immunodeficiency has been removed.
We are hindered by dealing with small numbers of patients,
rare diseases, changing protocols and transplant techniques, as
well as suboptimal methods of measuring immune function and
repertoire, and incomplete follow up information. Furthermore,
the information we gather in our retrospective studies often
pertains to historic rather than current practice (9). Importantly,
we are also, for many diseases, beginning to understand
the natural history of the disease without intervention with
transplantation, so that, for some of the more common diseases,
we are able to compare data between transplanted and non-
transplanted cohorts (10–14).
Nevertheless, we are entering an era where we are beginning
to understand the implications and consequences of previous
treatment practice. Data that we are now gathering are important
to aid our understanding of the impact of transplantation
on patient survival, immune function, long term organ
dysfunction/toxicity including fertility, and quality of life (refer
to chapter on Long Term Outcome and Immune Function
After Hematopoietic Stem Cell Transplantation for Primary
Immunodeficiency). It is now clear that early transplant
before the onset of significant infection or organ dysfunction
results in better outcomes for all immunodeficiencies (14,
15). In recent years, this knowledge and has heralded the
introduction of newborn screening to identify patients with
severe combined immunodeficiency before symptom onset (16)
(refer to chapter on Newborn Screening for SCID). Furthermore,
data are emerging to suggest that best early and longer term
outcomes of immune function require some degree of myeloid
engraftment which reflects hematopoietic stem cell progenitor
engraftment, and by implication, some form of pre-transplant
conditioning (4, 6, 17, 18).
Our understanding of the underlying genetic defects has led
us to realize that the degree of donor chimerism required for
optimal outcome differs depending on the primary disease—a
small percentage of donor myeloid chimerism in patients with
RAG-deficient severe combined immunodeficiency is sufficient
to restore complete T- and B-lymphocyte repertoire and function,
whereas incomplete donor chimerism in patients with Wiskott-
Aldrich syndrome is associated with an increased risk of
autoimmunity (7). Patients with gain-of-function diseases such
as STAT-1 or APDS appear to be more likely to experience
recurrence of disease manifestations when complete donor
chimerism is not achieved (19, 20) (refer to chapter on Long
Term Outcome and Immune Function After Hematopoietic Stem
Cell Transplantation for Primary Immunodeficiency). Detailed
information from larger cohorts of these patients, and those
treated with small molecules or specific pathway inhibitors will
help us to appropriately select patients for transplantation in the
future (21).
An understanding of the toxicities resulting from our
treatment approaches has driven the search for safer approaches
to therapy, and resulted in less toxic chemotherapy conditioning
regimens (22, 23), and is leading to approaches in antibody-
based conditioning regimens (24, 25) (refer to chapter on
Conditioning Perspectives for Primary Immunodeficiency Stem
cell Transplants) and safer approaches to curative therapy
including genetic correction of autologous cells by gene addition
(26) or gene editing (refer to chapter Autologous stem cell-
based gene therapy for inherited disorders: state-of-the-art and
future prospects). Our understanding of disease phenotype is
being complicated as the genetic revolution, powered by new
generation sequencing techniques and analysis of big data sets,
reveals patients with new, less severe phenotypes who harbor
mutations in genes previously understood to confer a severe
phenotype. At the same time as transplantation becomes safer,
it is also becoming clear that not everyone with a specific
primary immunodeficiency will require transplantation (27).
Nowhere is this dilemma sharper than in the expanding field
of adolescent and young adult transplantation for primary
immunodeficiency (28, 29) (refer to chapter on HSCT in
Adolescents and Young Adults with Primary Immunodeficiencies).
It should be acknowledged that most of our data pertain to
treatment of infants or children, and cannot be automatically
extrapolated to older patients. Recognizing who in this group
of patients requires transplantation, or can be adequately
managed with newly emerging immune-specific therapies is
probably one of the most difficult current challenges. The
need for collaboration between specialists, particularly through
organizations like the Inborn Errors Working Party of the
European Society for Blood and Marrow Transplantation
(IEWP-EBMT), the Primary Immune Deficiency Treatment
Consortium (PIDTC) of North America, the European Society
for Immunodeficiencies (ESID), and Stem CEll Transplant for
primary Immune Deficiencies in Europe (SCETIDE) and the
harvesting of good quality data into specialist registries has never
been greater.
As we celebrate 50 years of transplantation for primary
immunodeficiencies, we can acknowledge the tremendous
progress that we have achieved and look to a bright future for
our patients fuelled by enthusiastic international professional
collaborations between clinical specialists, basic scientists, patient
organizations and industry. These collaborations should now
focus on specific questions, identifying current knowledge (30),
and formulating practical research questions for the future (31).
Given the rarity of our patients, and relatively small cohorts of
patients, it is only by close collaborative efforts, ideally between
relevant societies such as those listed above, and careful use
of combined registries data, with carefully directed questions
that we will begin to gather the answers. Retrospective data
harvesting has formed the foundation of our knowledge base to
date, piecing together knowledge from different studies, often
measuring diverse parameters. Perhaps now, building on the
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knowledge we have now accumulated, is the time to design
prospective clinical trials for our patients, in order to accurately
answer outstanding questions.
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